by barry-jtcir | Feb 19, 2025 | Press Releases
GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA, CA, Feb. 19, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
by barry-jtcir | Feb 19, 2025 | Press Releases
On-demand video webcast now available here LA JOLLA, CA, Feb. 19, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
by barry-jtcir | Dec 23, 2024 | Press Releases
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
by barry-jtcir | Dec 6, 2024 | Press Releases
Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”)...
by barry-jtcir | Nov 21, 2024 | Press Releases
Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients and inhibition of iNKT cell activity with GRI-0621 ameliorates pulmonary...
